Hello, I am Christina Poe. I'm a physician at uh City of Hope. Uh, I am associate professor and um uh director of T cell lymphoma program, uh, here. So the landscape, the treatment landscape for PTCL specifically for T fliar helper cell lymphomas, um, Currently is. suboptimal. So as we all know already, the first line treatment is generally chop-based therapy, and that usually produces an overall response rate of, you know, uh, probably about 50%. Unfortunately, many, many patients who do initially respond to CHOP, um, relapse, um, and it's usually within the 1st 6 to 12 months of completion of CHOP. And the salvage regimens we have. Um, are few, um, at least the ones that are FDA approved, and, um, they are suboptimal in terms of response rates, um, with, with responses ranging anywhere from about 20% at best, maybe 30%. Um, all the trials that uh led to accelerated approval for these agents, um, were conducted as a single arm phase two trial, and so, We really Don't have any, and they were also also conducted uh as um Patients who were eligible for these trials were, were all PTCL and so we really don't have great Data on who are the patients who would best Um, respond or would, would have a, have the best, um, effectiveness from, from these agents. And so I think inte follicular helper as as well as, you know, other PTCL subtypes as a whole. Um, we, that's, that is, I think the main unmet need is we may know um data for or we may have data for PTCL as a whole, but when we look at specific subtypes of PTCL, we really don't know if that data can be extrapolated and can be applied to each subtype of PTCL.
Presenter
